Letters
Rivaroxaban: can we trust the evidence?
Quality control of point of care INR devices is essential
BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2019 (Published 12 April 2016) Cite this as: BMJ 2016;353:i2019
- D P Kitchen, lead scientist for point of care programmes1,
- S Kitchen, scientific director1,
- I Jennings, scientific programme manager1,
- T A L Woods, programme manager1,
- M Makris, professor of haematology2,
- I D Walker, director1
- 1UK NEQAS for Blood Coagulation, Pegasus House, Sheffield S10 2QD, UK
- 2Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
- dianne.kitchen{at}coageqa.org.uk
In response to Cohen’s article questioning the ROCKET AF data,1 we report on the need for point of care international normalised ratio (POC INR) testing devices to be quality controlled. Such testing should be subjected to the same quality control and quality management systems as laboratory INR testing. Appropriate and effective external quality assessment (EQA) for these …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.